Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

v3.10.0.1
STOCK-BASED COMPENSATION (Tables)
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]
The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock grants and stock option grants and recorded in connection with stock options granted to non-employee consultants:
 
 
 
Three Months Ended
September 30,
 
 
Nine Months Ended
September 30,
 
 
 
2018
 
 
2017
 
 
2018
 
 
2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Employee and director stock and stock option grants:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
$
31,409
 
 
$
46,059
 
 
$
102,161
 
 
$
102,780
 
General and administrative
 
 
132,487
 
 
 
130,265
 
 
 
410,752
 
 
 
470,304
 
Total stock-based compensation
 
$
163,896
 
 
$
176,324
 
 
$
512,913
 
 
$
573,084
 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
A summary of stock option activity is as follows:
 
 
 
Number of Shares Issuable Upon Exercise of Outstanding Options
 
 
Weighted Average Exercise Price
 
 
Weighted Average Remaining Contracted Term in Years
 
 
Aggregate Intrinsic Value
 
Outstanding at December 31, 2017
 
 
53,165
 
 
$
73.82
 
 
 
 
 
 
 
 
 
Granted
 
 
8,000
 
 
$
11.70
 
 
 
 
 
 
 
 
 
Expired
 
 
(2,204
)
 
$
491.43
 
 
 
 
 
 
 
 
 
Forfeited
 
 
(2,607
)
 
$
19.46
 
 
 
 
 
 
 
 
 
Outstanding at September 30, 2018
 
 
56,354
 
 
$
51.18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exercisable, September 30, 2018
 
 
34,142
 
 
$
67.13
 
 
 
7.61
 
 
$
—
 
Unvested, September 30, 2018
 
 
22,212
 
 
$
26.68
 
 
 
8.57
 
 
$
—
 
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] A summary of restricted stock activity is as follows:
 
Outstanding non-vested restricted stock at December 31, 2017
 
 
38,000
 
Granted
 
 
—
 
Vested
 
 
(12,666
)
Outstanding non-vested restricted stock at September 30, 2018
 
 
25,334